To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

About Us

The NCIC Clinical Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).

Faculty Researchers

Meet the Faculty Researchers


The information contained in this website is intended for use by NCIC Clinical Trials Group members at participating centres.

Recently Activated

  • HE1 
    Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases
  • I218 
    A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
  • I221 
    A Dose-Ranging Study of IPH2201 in Patients with High Grade Serous Carcinoma of Ovarian, Fallopian Tube or Peritoneal Origin
  • I226 
    A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens
  • MA36 
    Adjuvant Olaparib vs Placebo in Patients with BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer
  • MEC4 
    Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
  • SC24 
    Phase II Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy for Patients with Spinal Metastases
  • SRC7 
    Sorafenib vs Placebo in Desmoid Tumors or Aggressive Fibromatosis
  • Planned Trials

  • CEC5 
    Corticosteroid with either Bevacizumab or Placebo for Radionecrosis after Surgery for Brain Metastases
  • CEC6 
    Radiotherapy with Temozolomide versus Radiotherapy with PCV Chemotherapy for 1p/19q Co-deleted Anaplastic or Low Grade Glioma
  • I222 
    A Phase I/II Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme
  • MAC18 
    POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer
  • MAC19 
    A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
  • MEC5 
    A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
  • PR18 
    TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
  • MA37 
    A randomized phase III trial of Palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2 negative early breast cancer